CG189 |
Obesity: identification, assessment and management of overweight and obesity in children, young people and adults
|
Clinical guidelines
|
Diet, nutrition and obesity
|
PH56 |
Vitamin D: increasing supplement use among at-risk groups
|
Public health guidance
|
Diet, nutrition and obesity
|
TA326 |
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)
|
Technology appraisal guidance
|
Stomach cancer
|
IPG506 |
Insertion of an annular disc implant at lumbar discectomy
|
Interventional procedure guidance
|
Low back pain
|
IPG505 |
Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects
|
Interventional procedure guidance
|
Structural heart defects
|
QS72 |
NICE quality standard 72
|
Quality standards
|
|
MTG21 |
The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury
|
Medical technology guidance
|
Wound management
|
MTG20 |
Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers
|
Medical technology guidance
|
Skin conditions: general and other
|
TA325 |
Nalmefene for reducing alcohol consumption in people with alcohol dependence
|
Technology appraisal guidance
|
Alcohol
|
TA324 |
Dual‑chamber pacemakers for
symptomatic bradycardia due to sick sinus syndrome without
atrioventricular block (part review of technology appraisal guidance 88)
|
Technology appraisal guidance
|
Heart rhythm conditions
|
TA323 |
Erythropoiesis‑stimulating
agents (epoetin and darbepoetin) for treating anaemia in people with
cancer having chemotherapy (including review of TA142)
|
Technology appraisal guidance
|
Complications of cancer
|
TAG |
In development
Alcohol dependence - nalmefene [ID660]
|
Technology appraisals
|
|
QSD |
In development
Renal replacement therapy services
|
No hay comentarios:
Publicar un comentario